kitsvur.blogg.se

Available DOACs include the direct factor Xa inhibitors apixaban ( Eliquis), edoxaban ( Lixiana▼), and rivaroxaban ( Xarelto▼) and the direct thrombin inhibitor dabigatran etexilate ( Pradaxa). Report suspected adverse drug reactions associated with DOACs on a Yellow Card, including thromboembolic or haemorrhagic eventsĭirect-acting oral anticoagulants (DOACs) are approved for a variety of uses related to anticoagulation (see full indications in further information section). Monitor the reversal effects of andexanet alfa using clinical parameters anti-FXa assays should not be used to measure the effectiveness of andexanet alfa as the results may not be reliable Specific DOAC reversal agents are available for dabigatran, apixaban, and rivaroxaban Remind patients of the signs and symptoms of bleeding and encourage them to always read the patient information leaflet that accompanies their medicinesĮnsure patients with renal impairment receive an appropriate dose (see advice below) and monitor renal function during treatment to ensure dose remains appropriate Remain vigilant for signs and symptoms of bleeding complications during treatment, especially patients with increased bleeding risk

Use caution if prescribing direct-acting oral anticoagulants (DOACs) to patients at increased risk of bleeding (for example, older people or people with renal impairment)